PhRMA Reports Tout 5,400 Compounds in 'Robust' Pipeline

The Pharmaceutical Research and Manufacturers of America (PhRMA) served up two reports Thursday touting U.S. biopharma's "innovative and robust" pipeline of some 5,400 new molecular entities (NMEs), including more than 800 in Phase III studies.